

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

85. (Amended) A method of preparing an immunogenic composition, comprising the steps of:
- (a) providing an autologous target [diseased] tumor or pathogen infected cell;
 - (b) treating the tumor or pathogen infected cell with a cytokine to increase [increasing] concentration of a primary T cell activation [molecules] molecule or a costimulatory T cell activation [molecules] molecule in the target [diseased] tumor or pathogen infected cell;
 - (c) providing a [bridge molecule] bispecific monoclonal antibody including one or more binding sites for one or more costimulatory molecules on a surface of one or more T cells of a patient mammal;
 - (d) attaching the [bridge molecule] bispecific monoclonal antibody to the target [diseased] tumor or pathogen infected cell; and
 - (e) collecting a pharmaceutically effective amount of the target [diseased] tumor or pathogen infected cell with the attached [bridge molecule] bispecific monoclonal antibody.